Bibliography
- Kuehn BM . Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA297(3) , 249–251 (2007).
- Katz N , AdamsE, ChilcoatH et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin. J. Pain 23(8) , 648–660 (2007).
- Substance Abuse and Mental Health Services Administration. (2010). Results from the 2009 National Survey on Drug Use and Health: Volume II. Technical Appendices and Selected Prevalence Tables (Office of Applied Studies, NSDUH Series H-38B, HHS Publication No. SMA 10–4856 Appendices). Rockville, MD, USA.
- Substance Abuse and Mental Health Services Administration Office of Applied Studies. The DAWN report: trends in emergency department visits involving nonmedical use of narcotic pain relievers. Rockville, MD, USA (2010).
- Martins SS , StorrCL, ZhuH, ChilcoatHD. Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population. Drug Alcohol Depend.99(1–3) , 58–67 (2009).
- Zamloot M , ChaoW, KangL, RossJ, FuR. Remoxy®: a novel formulation of extended-release oxycodone developed using the ORADUR® technology. J. Appl. Res.10(3) , 88–99 (2010).
- Hays L , KirshKL, PassikSD. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J.Natl Compr. Canc. Netw.1(3) , 423–428 (2003).
- McCabe SE , BoydCJ, CranfordJA, TeterCJ. Motives for nonmedical use of prescription opioids among high school seniors in the United States: self-treatment and beyond. Arch. Pediatr. Adolesc. Med.163(8) , 739–744 (2009).
- Setnik B , RolandCL, ClevelandJM, WebsterL. The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med.12(4) , 618–631 (2011).
- De Kater AW , FriedmannN, ButeraPG et al. Clinical pharmacokinetics of oxycodone after single and multiple doses of Remoxy, a novel, abuse-resistant long-acting oxycodone formulation. Presented at: 3rd International Congress World Institute of Pain. Barcelona, Spain, 21–25 September 2004 (Abstract).
- Friedmann N , de Kater AW, Butera PG et al. Remoxy®, a novel drug candidate deters oxycodone abuse in humans. Presented at: 21st Annual Meeting of the American Academy of Pain Medicine. Palm Springs, USA, 23–27 February 2005 (Abstract 133).
- Friedmann N , KlutzaritzV, WebsterL. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med.12(5) , 755–760 (2011).
- Butler SF , BenoitC, BudmanSH et al. Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct. J. 3 , 5 (2006).
- Butler SF , BlackR, Grimes Serrano JM, Folensbee L, Chang A, Katz N. Estimating attractiveness for abuse of a not-yet-marketed “abuse-deterrent” prescription opioid formulation. Pain Med.11(1) , 81–91 (2010).
- Chou R , FanciulloGJ, FinePG et al.; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain10(2) , 113–130 (2009).
- Webster LR , BathB, MedveRA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin. Investig. Drugs18(3) , 255–263 (2009).
▪ Websites
- A Research Update from the National Institute on Drug Abuse. Prescription drug abuse: topics in brief [Internet]. Website of the National Institutes of Health. December 2010 http://drugabuse.gov/tib/prescription.html
- OxyContin indications and dosage. RxList.com. Owned and operated by WebMD (2011) www.rxlist.com/oxycontin-drug.htm
- FDA website. REMOXY XRT™ (oxycodone controlled-release) Capsules CII. Advisory Committee Briefing Materials for the Anesthetic Life Support Drugs Advisory Committee Meeting of November 13, 2008. www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4395b1-02-PAIN.pdf
- Primary endpoint of pivotal phase III clinical trial achieved for Remoxy™. [Press release]. DURECT Corporation. December 06, 2007 www.durect.com/wt/durect/page_name/pr_1196960615